Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Piotroski F-Score: 2 (As of Jul. 21, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605199 Hainan Huluwa Pharmaceutical Group Co Ltd SHSE:605199
50 GF Score
Price ¥5.48
GF Value ¥5.85
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Hainan Huluwa Pharmaceutical Group Co Piotroski F-Score?

Hainan Huluwa Pharmaceutical Group Co SHSE:605199 -3.18% 50 Piotroski F-Score is 2 as of Jul. 21, 2026, which is 50% below its 10-year median of 4.00. GuruFocus rates SHSE:605199 with a GF Score™ of 50/100 and a GF Value™ of ¥5.85 (Fairly Valued). The stock has 9 warning signs investors should review. Among 979 Drug Manufacturers companies, Hainan Huluwa Pharmaceutical Group Co ranks worse than 91.42% on this metric.

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hainan Huluwa Pharmaceutical Group Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Hainan Huluwa Pharmaceutical Group Co's Piotroski F-Score or its related term are showing as below:

SHSE:605199' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 7
Current: 2

During the past 10 years, the highest Piotroski F-Score of Hainan Huluwa Pharmaceutical Group Co was 7. The lowest was 1. And the median was 4.

Hainan Huluwa Pharmaceutical Group Co  (SHSE:605199) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Hainan Huluwa Pharmaceutical Group Co Piotroski F-Score Related Terms


Hainan Huluwa Pharmaceutical Group Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Hainan Huluwa Pharmaceutical Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hainan Huluwa Pharmaceutical Group Co Piotroski F-Score Chart

Hainan Huluwa Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 4.00 5.00 2.00 3.00

Hainan Huluwa Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 4.00 5.00 3.00 2.00

SHSE:605199 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Huluwa Pharmaceutical Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hainan Huluwa Pharmaceutical Group Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hainan Huluwa Pharmaceutical Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Hainan Huluwa Pharmaceutical Group Co's Piotroski F-Score falls into.


SHSE:605199
50GF Score
Hainan Huluwa Pharmaceutical Group Co Ltd SHSE:605199
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -21.937 + -13.624 + -276.16 + -28.958 = ¥-340.7 Mil.
Cash Flow from Operations was 112.781 + 44.337 + 78.362 + 61.877 = ¥297.4 Mil.
Revenue was 170.844 + 175.049 + 218.115 + 146.135 = ¥710.1 Mil.
Gross Profit was 87.637 + 56.34 + -11.678 + 36.71 = ¥169.0 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(3007.782 + 2913.606 + 2799.785 + 2602.954 + 2556.068) / 5 = ¥2776.039 Mil.
Total Assets at the begining of this year (Mar25) was ¥3,007.8 Mil.
Long-Term Debt & Capital Lease Obligation was ¥616.0 Mil.
Total Current Assets was ¥853.2 Mil.
Total Current Liabilities was ¥1,363.7 Mil.
Net Income was 13.666 + -158.641 + -156.908 + 24.347 = ¥-277.5 Mil.

Revenue was 418.42 + 143.64 + 380.959 + 336.827 = ¥1,279.8 Mil.
Gross Profit was 224.915 + 60.558 + 159.513 + 132.067 = ¥577.1 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(2928.288 + 3029.114 + 2819.581 + 2963.628 + 3007.782) / 5 = ¥2949.6786 Mil.
Total Assets at the begining of last year (Mar24) was ¥2,928.3 Mil.
Long-Term Debt & Capital Lease Obligation was ¥466.3 Mil.
Total Current Assets was ¥1,247.4 Mil.
Total Current Liabilities was ¥1,479.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hainan Huluwa Pharmaceutical Group Co's current Net Income (TTM) was -340.7. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hainan Huluwa Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 297.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-340.679/3007.782
=-0.11326586

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-277.536/2928.288
=-0.09477756

Hainan Huluwa Pharmaceutical Group Co's return on assets of this year was -0.11326586. Hainan Huluwa Pharmaceutical Group Co's return on assets of last year was -0.09477756. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Hainan Huluwa Pharmaceutical Group Co's current Net Income (TTM) was -340.7. Hainan Huluwa Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 297.4. ==> 297.4 > -340.7 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=615.983/2776.039
=0.22189278

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=466.288/2949.6786
=0.15808095

Hainan Huluwa Pharmaceutical Group Co's gearing of this year was 0.22189278. Hainan Huluwa Pharmaceutical Group Co's gearing of last year was 0.15808095. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=853.208/1363.671
=0.62566997

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1247.388/1479.862
=0.84290833

Hainan Huluwa Pharmaceutical Group Co's current ratio of this year was 0.62566997. Hainan Huluwa Pharmaceutical Group Co's current ratio of last year was 0.84290833. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Hainan Huluwa Pharmaceutical Group Co's number of shares in issue this year was 413.689. Hainan Huluwa Pharmaceutical Group Co's number of shares in issue last year was 405.783. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=169.009/710.143
=0.23799291

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=577.053/1279.846
=0.4508769

Hainan Huluwa Pharmaceutical Group Co's gross margin of this year was 0.23799291. Hainan Huluwa Pharmaceutical Group Co's gross margin of last year was 0.4508769. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=710.143/3007.782
=0.23610189

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1279.846/2928.288
=0.43706288

Hainan Huluwa Pharmaceutical Group Co's asset turnover of this year was 0.23610189. Hainan Huluwa Pharmaceutical Group Co's asset turnover of last year was 0.43706288. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+0+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hainan Huluwa Pharmaceutical Group Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 2 mean?
Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) has a Piotroski F-Score of 2 as of Jul. 21, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Hainan Huluwa Pharmaceutical Group Co and its competitors. This is 50% below median its historical median of 4.00. Over the past decade, Hainan Huluwa Pharmaceutical Group Co's Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, Hainan Huluwa Pharmaceutical Group Co ranks #895 out of 979 companies in the Drug Manufacturers industry, placing it in the top 91.4%.
Is Hainan Huluwa Pharmaceutical Group Co's Piotroski F-Score too high?
Hainan Huluwa Pharmaceutical Group Co's current Piotroski F-Score of 2 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Hainan Huluwa Pharmaceutical Group Co's value of 2 is 60% below this industry median. Based on the distribution chart, Hainan Huluwa Pharmaceutical Group Co ranks #895 out of 979 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hainan Huluwa Pharmaceutical Group Co has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hainan Huluwa Pharmaceutical Group Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hainan Huluwa Pharmaceutical Group Co ranks #895 out of 979 companies for Piotroski F-Score. This places Hainan Huluwa Pharmaceutical Group Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Hainan Huluwa Pharmaceutical Group Co's value of 2 is 60% below this benchmark. Historically, Hainan Huluwa Pharmaceutical Group Co's own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Hainan Huluwa Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hainan Huluwa Pharmaceutical Group Co's current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Hainan Huluwa Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hainan Huluwa Pharmaceutical Group Co's current Piotroski F-Score is 2, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hainan Huluwa Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.85, compared to a current price of ¥5.48 — trading 6.3% below its estimated fair value. The current Piotroski F-Score is 2, which is 50% below median its 10-year median of 4.00 and 60% below the Drug Manufacturers industry median of 5.00. Hainan Huluwa Pharmaceutical Group Co's overall GF Score™ is 50/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Hainan Huluwa Pharmaceutical Group Co (SHSE:605199), the current Piotroski F-Score is 2 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Overvalued in 2026?

Based on GuruFocus' analysis, Hainan Huluwa Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥5.48 is trading 6.3% below its estimated GF Value™ of ¥5.85. GuruFocus considers Hainan Huluwa Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for SHSE:605199:

  • Piotroski F-Score: 2 (50% below median its 10-year median of 4.00)
  • GF Value™: ¥5.85 vs. price of ¥5.48 (6.3% below fair value)
  • GF Score™: 50/100 with 9 warning signs
  • Industry Position: 60% below the Drug Manufacturers median (#895 of 979)

No single metric tells the full story. See the SHSE:605199 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hainan Huluwa Pharmaceutical Group Co Business Description

Address No. 8, Yaogu 4th Road, Phase II, Yaogu Industrial Park, Haikou National High-tech Zone, Hainan Province, Haikou, CHN, 570300
Hainan Huluwa Pharmaceutical Group Co Ltd is engaged in production and sales of Chinese patent medicines and chemical drugs. The company produces medicines for children's respiratory and digestive systems. Its products include star products, calabash, gourd dad, and gourd mom.
50GF Score

Get the complete analysis for SHSE:605199

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.48
Price
¥5.85
GF Value